๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood

โœ Scribed by Jeffrey S. Lobel; Richard T. O'Brien; Sue McIntosh; Gregg T. Aspnes; Robert L. Capizzi

Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
526 KB
Volume
43
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

Two groups of children with refractory acute lymphoblastic leukemia were treated with a regimen of methotrexate (MTX) and asparaginase (Asn'ase) based on studies of the effect of MTX in vitro on human lymphoblasts exposed to Asn'ase. Induction therapy in 12 children produced 4 complete remissions, 3 partial remissions, and 5 failures. Responsiveness to Asn'ase seemed necessary for successful induction with the drug combinations. Maintenance therapy in 18 children produced a median hematologic remission of 31 weeks (range 3-85 weeks). During remission, 2 children developed central nervous system leukemia and 2 died of infection. The mean maximally tolerated dose of MTX was 361 mg/m2. The results of this trial suggest therapeutic synergy in maintenance therapy and the capability of Asn'ase to attenuate MTX toxicity.

๐Ÿ“œ SIMILAR VOLUMES

Intermittent combined chemotherapy with
Intermittent combined chemotherapy with doxorubicin in recurrent childhood acute lymphoblastic leukemia
โœ Platt, M. P. Ward ;Mott, M. G. ;Eden, O. B. ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 298 KB

## Abstract A series of 14 children with bone marrow or testicular recurrence of acute lymphoblastic leukemia (ALL) and treated with pulsed combined chemotherapy incorporating doxorubicin is reviewed. All had been previously adequately treated according to established leukemia protocols. Median dis

Combination therapy with methotrexate, v
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia
โœ Alvaro Aguayo; Jorge Cortes; Deborah Thomas; Sherry Pierce; Michael Keating; Hag ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 72 KB ๐Ÿ‘ 2 views

BACKGROUND. L-asparaginase in combination with methotrexate has synergistic antileukemic activity in a schedule-dependent fashion. A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct prop